BioCryst Pharmaceuticals (BCRX) Aperçu de l'action
BioCryst Pharmaceuticals, Inc. est une société de biotechnologie qui développe et commercialise des médicaments pour l'angio-œdème héréditaire (HAE) et d'autres maladies rares. Plus de détails
| Score flocon de neige | |
|---|---|
| Évaluation | 5/6 |
| Croissance future | 3/6 |
| Performances passées | 0/6 |
| Santé financière | 2/6 |
| Dividendes | 0/6 |
BCRX Community Fair Values
Create NarrativeSee what 39 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
BioCryst Pharmaceuticals, Inc. Concurrents
Historique des prix et performances
| Historique des cours de bourse | |
|---|---|
| Prix actuel de l'action | US$10.45 |
| Plus haut sur 52 semaines | US$11.22 |
| Plus bas sur 52 semaines | US$6.00 |
| Bêta | 0.54 |
| Variation sur 1 mois | 27.59% |
| Variation sur 3 mois | 9.31% |
| Variation sur 1 an | 19.29% |
| Variation sur 3 ans | 46.56% |
| Variation sur 5 ans | -33.06% |
| Évolution depuis l'introduction en bourse | 60.77% |
Nouvelles et mises à jour récentes
Mise à jour du récit • Jul 07
BCRX: Rare Disease Deal Interest Will Support Long Term Upside Potential
Analysts have lifted their fair value estimate for BioCryst Pharmaceuticals from $13.00 to $14.00 per share, citing higher assumed long term profit margins and ongoing interest in rare disease stocks following recent sector M&A activity and increased Street price targets, including the move to $29.00 at Cantor Fitzgerald. Analyst Commentary Recent Street research around BioCryst Pharmaceuticals has centered on how the stock fits into a broader wave of rare disease M&A and what that might mean for its valuation and execution risks.
Mise à jour du récit • Jun 17
BCRX: Rare Disease Pipeline Progress And Licensing Deal Will Drive Shares
BioCryst Pharmaceuticals saw its consensus analyst price target raised by a few dollars into the mid $30s, as analysts pointed to updated assumptions around revenue growth, profit margins, and future P/E multiples to support their revised valuation work. Analyst Commentary Bullish analysts covering BioCryst Pharmaceuticals have recently adjusted their models and raised price targets, reflecting updated views on revenue growth assumptions, profit margins, and the P/E multiples they are willing to apply to the stock.Article d’analyse • Jun 16
BioCryst (BCRX) Stock After New HAE Data Presentation Is The Undervaluation Story Still Intact
BioCryst Pharmaceuticals (BCRX) drew investor attention after presenting new clinical and real world data on its hereditary angioedema therapies ORLADEYO and navenibart at the European Academy of Allergy and Clinical Immunology meeting in Istanbul. See our latest analysis for BioCryst Pharmaceuticals. At a share price of US$9.06, BioCryst has seen short term momentum pick up around the EAACI data, with a 1 day share price return of 4.14% and year to date share price return of 20.80%. However,...Recent updates
Mise à jour du récit • Jul 07
BCRX: Rare Disease Deal Interest Will Support Long Term Upside Potential
Analysts have lifted their fair value estimate for BioCryst Pharmaceuticals from $13.00 to $14.00 per share, citing higher assumed long term profit margins and ongoing interest in rare disease stocks following recent sector M&A activity and increased Street price targets, including the move to $29.00 at Cantor Fitzgerald. Analyst Commentary Recent Street research around BioCryst Pharmaceuticals has centered on how the stock fits into a broader wave of rare disease M&A and what that might mean for its valuation and execution risks.Mise à jour du récit • Jun 17
BCRX: Rare Disease Pipeline Progress And Licensing Deal Will Drive Shares
BioCryst Pharmaceuticals saw its consensus analyst price target raised by a few dollars into the mid $30s, as analysts pointed to updated assumptions around revenue growth, profit margins, and future P/E multiples to support their revised valuation work. Analyst Commentary Bullish analysts covering BioCryst Pharmaceuticals have recently adjusted their models and raised price targets, reflecting updated views on revenue growth assumptions, profit margins, and the P/E multiples they are willing to apply to the stock.Article d’analyse • Jun 16
BioCryst (BCRX) Stock After New HAE Data Presentation Is The Undervaluation Story Still Intact
BioCryst Pharmaceuticals (BCRX) drew investor attention after presenting new clinical and real world data on its hereditary angioedema therapies ORLADEYO and navenibart at the European Academy of Allergy and Clinical Immunology meeting in Istanbul. See our latest analysis for BioCryst Pharmaceuticals. At a share price of US$9.06, BioCryst has seen short term momentum pick up around the EAACI data, with a 1 day share price return of 4.14% and year to date share price return of 20.80%. However,...Seeking Alpha • Jun 15
BioCryst Pharmaceuticals: Management's Plans For Multibillion HAE Franchise Add Up
Summary BioCryst Pharmaceuticals, Inc. is upgraded to Buy, reflecting strong execution in HAE and a compelling pipeline with Orladeyo and navenibart. BCRX targets $1.8bn in revenues and $1bn in cash by 2033, leveraging best-in-class efficacy and less frequent dosing for navenibart to challenge market incumbents. Recent Q1 results showed 11% YoY Orladeyo revenue growth, robust non-GAAP profitability, and reaffirmed 2026 guidance, suggesting valuation remains attractive. Key risks for BCRX stock include intensifying competition, patent expiries post-2030, and potential clinical or manufacturing setbacks, but current momentum supports a 30–50% upside. Read the full article on Seeking Alpha
Mise à jour du récit • Jun 02
BCRX: HAE Portfolio Progress And European Deal Will Support Upside
Analysts have nudged their price targets on BioCryst Pharmaceuticals higher, with recent Street research pointing to a combined $4 increase as they update assumptions on revenue growth, profit margins, and future P/E expectations. Analyst Commentary Bullish Takeaways Bullish analysts point to updates in revenue assumptions as a key driver behind the combined US$4 increase in price targets, suggesting more confidence in the company’s ability to translate its pipeline and products into higher sales over time.Mise à jour du récit • May 16
BCRX: Astria Integration And Licensing Deal Will Support Hereditary Angioedema Expansion
Analysts have nudged their average price target on BioCryst higher by low single digits in recent weeks, citing reiterated long-term revenue goals following the Astria Therapeutics acquisition, ongoing confidence in Orladeyo and navenibart sales potential, and steadier expectations for future profitability and P/E levels. Analyst Commentary Recent research has leaned constructive on BioCryst, with several bullish analysts adjusting their price targets upward and reaffirming confidence in the company’s long term revenue framework following the Astria Therapeutics acquisition.Mise à jour du récit • May 01
BCRX: Astria Deal And FY26 Goals Will Support Rare Disease Upside
Analysts have inched their average price target on BioCryst Pharmaceuticals higher by $0.10 to $21.40, reflecting research that points to steady commercial execution, reiterated long term revenue goals following the Astria Therapeutics acquisition, and continued interest in the BCX17725 program as well as Orladeyo and navenibart sales potential. Analyst Commentary Recent research highlights a mix of enthusiasm and caution around BioCryst, with price targets edging higher and coverage resuming as analysts digest the Astria Therapeutics acquisition, updated guidance, and the company’s rare disease portfolio.Mise à jour du récit • Apr 17
BCRX: Astria Integration And 2031 Debt Structure Will Support Hereditary Angioedema Expansion
Narrative Update Analysts have nudged their price targets on BioCryst Pharmaceuticals higher by $1. This reflects continued confidence in management's reiterated FY26 guidance, the integration of the Astria Therapeutics acquisition, and the longer term potential they see in Orladeyo and navenibart.Mise à jour du récit • Apr 03
BCRX: Astria Acquisition And FY26 Guidance Will Support Long-Term Revenue Potential
Analysts lifted their price target on BioCryst Pharmaceuticals to $22 from $21, citing steady forward guidance, reaffirmed peak revenue goals following the Astria Therapeutics acquisition, and confidence in Orladeyo and the BCX17725 program as key factors supporting the updated outlook. Analyst Commentary Bullish Takeaways Bullish analysts see the higher price target as supported by reiterated FY26 guidance and peak revenue goals, which they view as evidence that management is confident in the current growth plan.Mise à jour du récit • Mar 20
BCRX: Astria Acquisition And FY26 Outlook Will Support Long Term Upside
Analysts lifted their price targets on BioCryst to a range of $17 to $22, citing steady FY26 guidance, reaffirmed peak revenue goals, and confidence in the Astria Therapeutics acquisition and BCX17725 data timeline as key supports for the higher valuations. Analyst Commentary Recent Street research on BioCryst highlights a mix of optimism around the Astria Therapeutics acquisition, reaffirmed FY26 guidance, and the commercial trajectory of Orladeyo, alongside growing interest in the BCX17725 program as a potential long term driver.Mise à jour du récit • Mar 05
BCRX: Astria Acquisition And FY26 Outlook Will Support Long-Term HAE Leadership
Analysts have raised their blended price target on BioCryst Pharmaceuticals to about $21.30 from $20.50, citing reaffirmed FY26 guidance, reiterated peak revenue goals after the Astria Therapeutics acquisition, and continued confidence in the commercial ramp and the BCX17725 data timeline. Analyst Commentary Bullish Takeaways Bullish analysts see the higher blended price targets, up to about $22, as reflecting confidence in execution on the FY26 guidance and the longer term revenue framework.Mise à jour du récit • Feb 19
BCRX: Astria Acquisition Will Drive Hereditary Angioedema Franchise Expansion
Analysts have reaffirmed their $32.00 fair value estimate for BioCryst Pharmaceuticals and supported a $17.00 price target, citing expectations for Orladeyo to potentially reach $900m in sales by 2029 and for navenibart to approach $1b in risk adjusted sales following the Astria Therapeutics acquisition. Analyst Commentary Bullish analysts view the reaffirmed US$32.00 fair value estimate and the US$17.00 price target as grounded in a clearer revenue roadmap, with both Orladeyo and navenibart framed as key building blocks of the story rather than optional upside.Mise à jour du récit • Feb 05
BCRX: Pediatric Approval And 2031 Financing Will Strengthen Long Term Outlook
Narrative Update Overview Analysts have raised their price target on BioCryst Pharmaceuticals from US$11.00 to US$13.00, reflecting updated assumptions on revenue, profit margins, discount rate and future P/E multiples in their valuation work. What's in the News Entered a new loan agreement with Blackstone Alternative Credit Advisors LP and Blackstone Life Sciences Advisors L.L.C. for term loans with gross proceeds of US$400 million, issued in multiple tranches and maturing on January 23, 2031, with quarterly interest-only payments and principal due at maturity (company announcement).Mise à jour du récit • Jan 22
BCRX: Pediatric Expansion And 2025 Profitability Outlook Will Support Long-Term HAE Leadership
Narrative Update Overview Analysts now see fair value for BioCryst Pharmaceuticals at US$20.50 per share, a US$0.10 adjustment that reflects updated assumptions on revenue growth, profit margins, discount rate, and future P/E levels. What's in the News BioCryst issued full year 2026 earnings guidance, with total revenue expected in a range of US$635 million to US$660 million (company guidance).Mise à jour du récit • Jan 08
BCRX: Astria Acquisition Will Extend HAE Leadership With Long Acting Injectable Through 2042
Narrative Update: BioCryst Pharmaceuticals The updated analyst price target for BioCryst Pharmaceuticals has moved modestly higher to about $20.60 from $20.40, with analysts pointing to the planned $700m acquisition of Astria Therapeutics, expected SG&A synergies, and the potential of HAE candidate navenibart to support BioCryst's hereditary angioedema franchise as key reasons for their revised view. Analyst Commentary Street research around BioCryst's planned US$700m acquisition of Astria Therapeutics clusters around the same core themes, but with different levels of enthusiasm about execution risk, competitive pressure, and valuation.Mise à jour du récit • Dec 24
BCRX: Astria Acquisition Will Extend Hereditary Angioedema Leadership Through Navenibart
We raise our BioCryst Pharmaceuticals fair value estimate to $32.00 from $28.15, as analysts highlight the accretive $700M Astria Therapeutics acquisition and its potential to extend the company’s hereditary angioedema leadership with long acting navenibart through the next decade. Analyst Commentary Analysts with a positive view on the stock are broadly endorsing BioCryst's acquisition of Astria Therapeutics, describing it as a value-accretive move that enhances the company’s hereditary angioedema portfolio and extends its potential growth runway into the 2030s and beyond.Mise à jour du récit • Dec 10
BCRX: Astria Acquisition Will Extend HAE Leadership With Long-Acting Injectable Through 2042
Analysts have lifted their average price targets on BioCryst Pharmaceuticals by a mid-teens dollar amount into the mid to high $20s per share range, citing the proposed $700M acquisition of Astria Therapeutics as a strategically sound, earnings-accretive move that extends the company’s hereditary angioedema leadership and reduces long-term growth risk. Analyst Commentary Street research following the Astria Therapeutics deal skews constructive, with most price target revisions reflecting higher confidence in BioCryst’s long term growth profile and durability in hereditary angioedema, even as investors weigh near term dilution and competitive risks.Mise à jour du récit • Nov 26
BCRX: Acquisition Will Extend HAE Franchise With New Long-Acting Candidate Through 2042
BioCryst Pharmaceuticals’ fair value estimate has increased from $19.73 to $20.40 per share. Analysts cite the company’s acquisition of Astria Therapeutics and improved long-term growth prospects following recent price target raises by multiple firms.Mise à jour du récit • Nov 12
BCRX: Acquisition Will Drive Earnings Upside With New HAE Candidate Through 2042
BioCryst Pharmaceuticals' fair value estimate has been adjusted downward by approximately $0.55 per share, as analysts incorporate the strategic rationale and expected synergies following the announced acquisition of Astria Therapeutics. Analyst Commentary Market observers have provided a range of insights following BioCryst Pharmaceuticals' acquisition of Astria Therapeutics.Article d’analyse • Nov 06
Earnings Beat: BioCryst Pharmaceuticals, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Last week saw the newest third-quarter earnings release from BioCryst Pharmaceuticals, Inc. ( NASDAQ:BCRX ), an...Mise à jour du récit • Oct 29
Acquisition Of Leading HAE Therapy Candidate Will Drive Future Market Expansion
Analysts have raised their price target for BioCryst Pharmaceuticals from $18.50 to approximately $20.27 per share. This change reflects optimism about the company's acquisition of Astria Therapeutics and its anticipated impact on future growth and market position.Mise à jour du récit • Oct 14
Expanding Rare Disease Pipeline Will Open New Markets
Analysts have raised their fair value estimate for BioCryst Pharmaceuticals to $18.50 from $16.73. They cited the anticipated long-term benefits and strategic alignment from the recent Astria Therapeutics acquisition, despite some near-term uncertainties.Article d’analyse • Aug 07
BioCryst Pharmaceuticals, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
A week ago, BioCryst Pharmaceuticals, Inc. ( NASDAQ:BCRX ) came out with a strong set of quarterly numbers that could...Nouveau récit • May 09
ORLADEYO Pipeline Will Deliver New Therapeutic Opportunities
ORLADEYO's revenue growth, patient conversion, and reduced royalty payments enhance profitability, cash flow, and financial stability for BioCryst Pharmaceuticals.Seeking Alpha • Feb 25
BioCryst: Upgrading On Strong 2024 Orladeyo Sales, But I Remain Skeptical
Summary I initially rated BioCryst a "Sell" in November 2023, but am now upgrading to "Hold" as the company has outperformed my expectations, despite competitive pressures. Orladeyo, BioCryst's main revenue source, saw impressive growth in 2024, but faces significant competition and may not reach management's $1bn annual revenue target in my view. Q4 2024 earnings showed a notable improvement with a reduced GAAP operating loss and a positive non-GAAP operating profit, but guidance for ~22% growth led to a sell-off. Despite promising near-term growth and potential label expansions, long-term risks and reliance on Orladeyo remain concerns, making the stock fairly valued at this time in my view. Read the full article on Seeking AlphaArticle d’analyse • Feb 15
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Fly 25% But Investors Aren't Buying For Growth
The BioCryst Pharmaceuticals, Inc. ( NASDAQ:BCRX ) share price has done very well over the last month, posting an...Rendement pour les actionnaires
| BCRX | US Biotechs | US Marché | |
|---|---|---|---|
| 7D | 6.2% | 0.02% | 0.6% |
| 1Y | 19.3% | 36.1% | 19.5% |
Rendement vs Industrie: BCRX a sous-performé le secteur US Biotechs qui a rapporté 36.1 % au cours de l'année écoulée.
Rendement vs marché: BCRX correspond au marché US qui a rapporté 19.5 % au cours de l'année écoulée.
Volatilité des prix
| BCRX volatility | |
|---|---|
| BCRX Average Weekly Movement | 7.2% |
| Biotechs Industry Average Movement | 10.4% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.2% |
Cours de l'action stable: BCRX n'a pas connu de volatilité de prix significative au cours des 3 derniers mois par rapport au marché US.
Volatilité au fil du temps: La volatilité hebdomadaire de BCRX ( 7% ) est restée stable au cours de l'année écoulée.
À propos de l'entreprise
| Fondée | Salariés | PDG | Site web |
|---|---|---|---|
| 1986 | 435 | Charlie Gayer | www.biocryst.com |
BioCryst Pharmaceuticals, Inc. est une société de biotechnologie qui développe et commercialise des médicaments destinés au traitement de l’œdème angioneurotique héréditaire (HAE) et d’autres maladies rares. La société commercialise le peramivir injectable, un inhibiteur de la neuraminidase administré par voie intraveineuse pour le traitement de la grippe aiguë non compliquée et de la grippe saisonnière, sous les noms de RAPIVAB, RAPIACTA et PERAMIFLU ; ainsi que l’ORLADEYO, un inhibiteur de la sérine protéase administré par voie orale pour le traitement de l’AOH. Elle développe également le BCX17725, un traitement protéique contre le syndrome de Netherton, actuellement en phase 1 ; l’Avoralstat, un inhibiteur de la kallikréine plasmatique oculaire destiné au traitement de l’œdème maculaire diabétique, actuellement en phase 1 ; le Navenibart, un anticorps monoclonal inhibiteur de la kallikréine plasmatique destiné au traitement de l’AOH, qui en est à la phase 3 ; le BCX17725, un traitement protéique expérimental inhibiteur de la KLK5 destiné au traitement du syndrome de Netherton, qui en est à la phase 1 d’essai clinique ; le STAR-0310, un anticorps monoclonal antagoniste de l’OX40 destiné au traitement de la dermatite atopique, qui en est à l’essai de phase 1a.
BioCryst Pharmaceuticals, Inc. Résumé des fondamentaux
| BCRX statistiques fondamentales | |
|---|---|
| Capitalisation boursière | US$2.72b |
| Bénéfices(TTM) | -US$457.98m |
| Recettes(TTM) | US$885.72m |
3.0x
Ratio P/S-5.8x
Ratio P/ELe site BCRX est-il surévalué ?
Voir Juste valeur et analyse de l'évaluationBénéfices et recettes
| BCRX compte de résultat (TTM) | |
|---|---|
| Recettes | US$885.72m |
| Coût des recettes | US$207.02m |
| Marge brute | US$678.70m |
| Autres dépenses | US$1.14b |
| Les revenus | -US$457.98m |
Derniers bénéfices déclarés
Mar 31, 2026
Prochaine date de publication des résultats
s/o
| Résultat par action (EPS) | -1.80 |
| Marge brute | 76.63% |
| Marge bénéficiaire nette | -51.71% |
| Ratio dettes/capitaux propres | -152.2% |
Quelles ont été les performances à long terme de BCRX?
Voir les performances historiques et les comparaisonsAnalyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/07/10 01:41 |
| Cours de l'action en fin de journée | 2026/07/10 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d'analyse utilisé pour générer ce rapport sont disponibles sur notre page Github, nous proposons également des guides pour apprendre à utiliser nos rapports et des tutoriels sur YouTube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
BioCryst Pharmaceuticals, Inc. est couverte par 27 analystes. 9 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Tazeen Ahmad | BofA Global Research |
| Dae Gon Ha | BTIG |
| Steven Seedhouse | Cantor Fitzgerald & Co. |